Interleukin-17F signaling requires ubiquitination of interleukin-17 receptor via TRAF6

被引:40
作者
Rong, Zhili
Cheng, Long
Ren, Yongming
Li, Zhiyong
Li, Yinghua
Li, Xueni
Li, Hongge
Fu, Xin-Yuan
Chang, Zhijie [1 ]
机构
[1] Tsinghua Univ, Dept Biol Sci & Biotechnol, Sch Med, Inst Biomed,State Key lab Biomembrane & Membrane, Beijing 100084, Peoples R China
[2] Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN USA
基金
中国国家自然科学基金;
关键词
IL-17F; IL-17R; TRAF6; ubiquitination; IL-17; T(H)17 cells; signaling;
D O I
10.1016/j.cellsig.2007.01.025
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Interleukin-17F (IL-17F), together with interleukin-17A (IL-17 or IL-17A), is a marker of T(H)17 cells, anew lineage of effector CD4+ T cells to contribute to pathogenesis of a growing list of autoimmune and inflammatory diseases, such as experimental autoimmune encephalitis (EAE) and collagen-induced arthritis (CIA). IL-17F, similar to IL-17A, was reported to employ interleukin-17 receptor (IL-17R or IL-17RA) for signaling but the downstream cascades remain largely elusive. Here we report that TRAF6 interacts with IL-17R and mediates ubiquitination of the receptor. We observed that IL-17F and IL-17A could induce IL-17 R ubiquitination and DN-TRAF6, a dominant-negative mutant, could block IL-17F- but not IL-17A-triggered ubiquitination of IL-17R. Moreover, we showed that the ubiquitination of IL-17R was positively correlated with the downstream signaling, as evaluated by a luciferase reporter driven by a putative native promoter of 24p3, an IL-17 targeted gene. Our results indicate that ubiquitination of IL-17R mediated by TRAF6 plays a critical role in IL-17F signaling. This study, for the first time, reveals a possible molecular mechanism that the initiation of the IL-17F/IL-17R signaling pathway requires the receptor ubiquitination by TRAF6. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1514 / 1520
页数:7
相关论文
共 38 条
[1]   Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J].
Aggarwal, S ;
Ghilardi, N ;
Xie, MH ;
de Sauvage, FJ ;
Gurney, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1910-1914
[2]  
Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1
[3]   Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells [J].
Batten, Marcel ;
Li, Ji ;
Yi, Sothy ;
Kljavin, Noelyn M. ;
Danilenko, Dimitry M. ;
Lucas, Sophie ;
Lee, James ;
de Sauvage, Frederic J. ;
Ghilardi, Nico .
NATURE IMMUNOLOGY, 2006, 7 (09) :929-936
[4]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238
[5]   Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor [J].
Chang, Seon Hee ;
Park, Heon ;
Dong, Chen .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (47) :35603-35607
[6]  
Chung JY, 2002, J CELL SCI, V115, P679
[7]   Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO [J].
Ea, CK ;
Deng, L ;
Xia, ZP ;
Pineda, G ;
Chen, ZJJ .
MOLECULAR CELL, 2006, 22 (02) :245-257
[8]   Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling [J].
Geetha, T ;
Jiang, JX ;
Wooten, MW .
MOLECULAR CELL, 2005, 20 (02) :301-312
[9]   Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J].
Harrington, LE ;
Hatton, RD ;
Mangan, PR ;
Turner, H ;
Murphy, TL ;
Murphy, KM ;
Weaver, CT .
NATURE IMMUNOLOGY, 2005, 6 (11) :1123-1132
[10]   IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding [J].
Hymowitz, SG ;
Filvaroff, EH ;
Yin, JP ;
Lee, J ;
Cai, LP ;
Risser, P ;
Maruoka, M ;
Mao, WG ;
Foster, J ;
Kelley, RF ;
Pan, GH ;
Gurney, AL ;
de Vos, AM ;
Starovasnik, MA .
EMBO JOURNAL, 2001, 20 (19) :5332-5341